Medicinal Technologies is a pioneering biopharmaceutical and biotechnology company dedicated to the research, development, and advancement of innovative therapeutic solutions. Our mission is to develop science-backed treatments and novel biopharmaceutical formulations that target complex disorders at their biological root.

Through rigorous clinical research, advanced data analysis, and precision protocol development, we are working to bridge the gap between cutting-edge science and personalized patient care.

Our goal is clear: to deliver innovative, effective, and targeted therapies that improve long-term health outcomes—moving beyond symptom management to address the true underlying mechanisms of disease.

By combining evidence-based medicine with next-generation biotechnologies, Medicinal Technologies is helping shape the future of personalized treatment strategies and redefining what’s possible in modern healthcare.

One of our key breakthroughs comes from our lead medical scientist, Dr. Tejeda, who created The Tejeda Equation. This revolutionary equation outlines the mechanism of action for how Endometriosis develops. The equation, which reads as:

(∑(σX GnRH ⇒ JEG3f )+ (σα ^βER ) ∴ NR3A1 ≥ 300-437pg/ml e (τ +30dy)∆ δEEC)

has reshaped how we approach the molecular interactions underlying Endometriosis, offering new insights for improved diagnosis and treatment options. Dr. Tejeda’s work continues to inspire innovation within the field of biopharmaceuticals.

We are a proud U.S. manufacturer. All of our manufacturing, research and development, and operations are conducted entirely within the United States.